Angiodynamics (ANGO) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $269.7 million.
- Angiodynamics' Liabilities and Shareholders Equity fell 751.68% to $269.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $1.1 billion, marking a year-over-year decrease of 1033.27%. This contributed to the annual value of $280.1 million for FY2025, which is 1181.32% down from last year.
- Latest data reveals that Angiodynamics reported Liabilities and Shareholders Equity of $269.7 million as of Q4 2025, which was down 751.68% from $265.6 million recorded in Q3 2025.
- In the past 5 years, Angiodynamics' Liabilities and Shareholders Equity ranged from a high of $582.2 million in Q1 2021 and a low of $265.6 million during Q3 2025
- For the 5-year period, Angiodynamics' Liabilities and Shareholders Equity averaged around $443.2 million, with its median value being $516.1 million (2023).
- Per our database at Business Quant, Angiodynamics' Liabilities and Shareholders Equity skyrocketed by 74.07% in 2022 and then crashed by 4163.6% in 2024.
- Over the past 5 years, Angiodynamics' Liabilities and Shareholders Equity (Quarter) stood at $554.1 million in 2021, then rose by 0.74% to $558.2 million in 2022, then fell by 10.5% to $499.6 million in 2023, then crashed by 41.64% to $291.6 million in 2024, then dropped by 7.52% to $269.7 million in 2025.
- Its Liabilities and Shareholders Equity was $269.7 million in Q4 2025, compared to $265.6 million in Q3 2025 and $280.1 million in Q2 2025.